Hemostemix (CVE:HEM) Stock Price Up 28.6% – Time to Buy?

by · The Cerbat Gem

Hemostemix Inc. (CVE:HEM – Get Free Report) shares rose 28.6% during mid-day trading on Wednesday . The company traded as high as C$0.14 and last traded at C$0.14. Approximately 421,375 shares traded hands during mid-day trading, an increase of 16% from the average daily volume of 363,410 shares. The stock had previously closed at C$0.11.

Hemostemix Stock Performance

The company has a market capitalization of C$12.63 million, a P/E ratio of -7.25 and a beta of 0.20. The company has a 50-day simple moving average of C$0.09 and a 200 day simple moving average of C$0.07.

Hemostemix Company Profile

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.

See Also